Big Phar­ma vet John Hohnek­er takes the reins at Anokion; Hep­tares co-founder Fiona Mar­shall re­signs from par­ent com­pa­ny So­sei

→ Hav­ing worked in a slate of se­nior po­si­tions in phar­ma and biotech, John Hohnek­er is now tak­ing the reins of Anokion as pres­i­dent and CEO. Most re­cent­ly he was pres­i­dent of R&D at For­ma Ther­a­peu­tics, where he guid­ed the com­pa­ny from dis­cov­ery stage to clin­i­cal tri­als. In Hohnek­er, the Lau­sanne, Switzer­land-head­quar­tered biotech gets an ex­pe­ri­enced ex­ec who’s spent a com­bined 20 years at GSK and No­var­tis. He’s been in­volved with the de­vel­op­ment, ap­proval and com­mer­cial­iza­tion of such drugs as Cosen­tyx, Gleevec, and Afin­i­tor. His fo­cus will be on de­vel­op­ing the biotech’s im­mune tol­er­ance plat­form for au­toim­mune dis­ease, which has at­tract­ed Cel­gene to ink a col­lab­o­ra­tion deal with an op­tion to buy.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.